Epidemiological Study of the Markers of Aging in the Cohort of Patient HIV in Brest
VIHVA
1 other identifier
observational
213
1 country
1
Brief Summary
RATIONALE: HIV pathology has been associated with accelerated aging of the infected organism, with no known knowledge of virus, immunosuppression, immune response stimulation, antiretroviral toxicity, and "classic" risks. The data are in good standing from a multicenter cohort with high statistical power but very heterogeneous and not exhaustive. A complementary approach by small, comprehensive cohorts is desirable. POPULATION CONCERNED: HIV-positive persons OBJECTIVE To describe the aging of the physiological functions of people living with HIV. SECONDARY OBJECTIVES Assess the determinants (virus / HAART / Immunity / environment) Compare to the general population (historical comparisons) Compare to main body functions MAIN EVALUATION CRITERIA respiratory functional tests, memory test, IMTc, ECG, creatininemia, cancer, Fibroscan, bone densitometry... SECONDARY EVALUATION CRITERIA Age, sex, phototype, CD4 lymphocytes count, viral load, nadir CD4, antiretroviral exposure, alcohol, tobacco ... METHODOLOGY Monocentric retrospective study STATISTICS Frailty model, chi2 test, test U INCLUSION CRITERIA Seropositive for HIV, age\>18 years Follow-up at least once in the Internal Medicine department between 1995 and 2018 CRITERIA OF EXCLUSION Refusal of the patient or unreachable patient NUMBER OF PATIENTS Between 200 and 300 CALENDAR Duration of inclusions: 3 months Duration of participation of the patient: 20 years (retrospectives ...) Duration of the study: 1 year
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2017
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 8, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2017
CompletedFirst Submitted
Initial submission to the registry
October 1, 2018
CompletedFirst Posted
Study publicly available on registry
August 15, 2024
CompletedAugust 15, 2024
August 1, 2024
12 months
October 1, 2018
August 13, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (7)
renal aging
creatinin level, creatinin clearance, microalbuminuria
yearly
pulmonary aging
respiratory functional test
at last one
liver aging
elastometry (Fibroscan\*)
at last one
neurological aging
memory tests
at last one
vascular aging
intima-media thickness, systolic and diastolic blood pressure
at last one
Bone aging
osteodensitometry
at last one
heart aging
ECG, echography
at last one
Eligibility Criteria
All persons followed between 2003 to 2018 in the one center (Internal Médicine) of the West Brittany cohort
You may qualify if:
- HIV positive persons followed in Internal Medicine departement of Brest University Hospital
You may not qualify if:
- opposition of the study
- \<18 ans
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Internal Medicine Department of University Hospital
Brest, 29200, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Luc de Saint-Martin, MD, PhD
University Hospital, Brest
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 1, 2018
First Posted
August 15, 2024
Study Start
January 8, 2017
Primary Completion
December 31, 2017
Study Completion
December 31, 2017
Last Updated
August 15, 2024
Record last verified: 2024-08